Navigation Links
Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance
Date:1/23/2013

patients. These trials included two studies evaluating the safety and effectiveness of OFIRMEV in the treatment of pain, and one study evaluating OFIRMEV in the treatment of fever. The effectiveness of OFIRMEV for the treatment of acute pain and fever has not been studied in pediatric patients less than 2 years of age.

Important Safety Information
Do not exceed the maximum recommended daily dose of acetaminophen. Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death. OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment. OFIRMEV should be administered only as a 15-minute intravenous infusion. Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur. Do not use in patients with acetaminophen allergy. The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients. The antipyretic effects of OFIRMEV may mask fever in patients treated for post-surgical pain.

For more information, please see the complete OFIRMEV Prescribing Information, available at www.OFIRMEV.com or www.cadencepharm.com.

About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting.
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
2. Cadence Pharmaceuticals to Host Analyst and Investor Day
3. Cadence to Open Finished Medical Device Facility
4. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012
5. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
6. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012
7. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2012 In Boston On September 5, 2012
8. Cadence Pharmaceuticals To Present At The Wedbush PACGROW Life Sciences Management Access Conference In New York City On August 14, 2012
9. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2012 Financial Results On August 2, 2012
10. Cadence Pharmaceuticals Reports First Quarter 2012 Financial Results
11. Vanda Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on February 12, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... InformEx, North America,s leading business ... hold the 30 th edition of its annual conference ... from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... chemical and specialty chemical companies will take part in the ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... , , ... Orphan Drug Designation , SILVER SPRING, Md., Dec. 23 ... more transparent and accessible, the FDA has scheduled a series of ... unfamiliar with the process. The FDA can grant a special status, ...
... , , PHILADELPHIA, Dec. 23 URL Pharma today announced ... initiative designed to save patients money on their health insurance co-payment ... no more than $25 for a Colcrys prescription, which equates to ... the prevention and treatment of gout flares and for the treatment ...
Cached Medicine Technology:FDA: Orphan Drug Workshops Scheduled For Feb. 25-26 and Aug. 3-4, 2010 2URL Pharma Launches Co-Pay Assistance Program for Colcrys(R) 2URL Pharma Launches Co-Pay Assistance Program for Colcrys(R) 3URL Pharma Launches Co-Pay Assistance Program for Colcrys(R) 4
(Date:7/10/2014)... (July 10, 2014) Men who experience hot flashes ... may find relief from their silent suffering if ... to findings from a Baylor University case study., After ... who had uncontrolled hot flashes following prostate cancer surgery ... but also an impressive improvement in sleep quality, according ...
(Date:7/9/2014)... 10, 2014 -- The World Health Organization recommends that ... moderate to vigorous physical activity (MVPA) each day. ... MVPA during school hours. Therefore, it stands to ... increase MVPA. In a new study scheduled for ... confirmed that time spent outdoors after school was positively ...
(Date:7/9/2014)... first time, researchers have access to detailed information about ... care. A new study, called Our Health Counts, uses ... faced by urban Aboriginal people in Canada according ... findings, published today in BMJ Open , illustrate ... general population. , Researchers interviewed 554 First Nations adults ...
(Date:7/9/2014)... Researchers at the Perelman School of Medicine at ... Park Cancer Institute have received an $8 million grant ... effects of photodynamic light therapy (PDT) in patients with ... that most often manifests itself in the lining of ... to asbestos. The grant will fund a clinical trial ...
(Date:7/9/2014)... in almost all types of cancer sends the protein ... fuel a tumour,s uncontrolled growth, new research suggests. , ... a molecular trigger responsible for ratcheting up activity of ... makes the building blocks cancer cells need to keep ... called SREBP, controls the flow of messages to the ...
Breaking Medicine News(10 mins):Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2
... MADISON, Wis., and BIRMINGHAM, Ala., Sept. 14 ... is now offering a specialized,professional liability program ... being made available through Physicians Insurance Company,of ... "We are pleased to have the ...
... (HealthDay News) -- It,s under your movie seat and glued ... relief may be in sight. This week, researchers say they,ll ... at the BA Festival of Science in York, England. , ... and sidewalks, and preliminary tests indicate that it degrades naturally ...
... STAUNTON, Va., Sept. 14 Michael Bond has,been ... joins,the company following nearly 30 years in various ... Director of Blade Process,Engineering. Bond has a wealth ... advancement of leading edge technologies for,IncisionTech and Specialty ...
... Sept. 14 Stryker,Corporation (NYSE: SYK ) announced ... September 25, 2007 - 4:30 p.m. Eastern Time ... New York A simultaneous webcast of the Company,s ... via the For Investors page. The,presentation for the ...
... Sept. 14 Most people looking for tax advice,usually ... usually see,mechanics, right? Here,s more on a new report ... and questions are actually not seeing the pros,trained in ... at:, http://media.medialink.com/WebNR.aspx?story=33829 Registered journalists can access video, ...
... Mylan Laboratories Inc.,(NYSE: MYL ) today announced ... of Senior Vice President and Chief Compliance Officer. ... where she was,Director of Compliance for Latin America, ... for all compliance-related matters in those,regions. Prior to ...
Cached Medicine News:Health News:ProAssurance Group Offers Coverage for Community Based Hospitals in Michigan 2Health News:Specialty Blades, Inc. Expands Management Team With New VP Engineering 2Health News:Stryker to Present at Investor Conference 2Health News:Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer 2
...
... System is a complete anterior ... portable, it offers high-end performance ... console. It also provides all ... segment surgery. These include Irrigation, ...
... tool designed for ophthalmic surgeons. ... reliable, safe and easy to ... (one year for ultrasonic handpiece). ... console, phaco handpiece, foot pedal, ...
Oncoseed sterile convenience pack contains fifteen Oncoseed seeds (Model 6711) loaded into a Mick disposable cartridge and steam sterilized ready to use....
Medicine Products: